The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

This study tests a combination bladder wash (intravesical) treatment using mitomycin-C and gemcitabine given alternately for patients with high-risk non-muscle-invasive bladder cancer (cancer that stays in the bladder lining) that has not responded to the standard BCG treatment. **You may be eligible if...** - You are 20 or older - You have confirmed high-risk bladder cancer (T1, high-grade, or with CIS) that did not respond to BCG therapy - You recently had a procedure to remove the bladder tumor (TURBT) within the past 8 weeks - You are not eligible for or have refused radical bladder removal surgery **You may NOT be eligible if...** - Your cancer has grown into the muscle of the bladder wall - Your cancer has spread to lymph nodes or other parts of the body - You have a rare non-transitional cell type of bladder cancer - You received systemic chemotherapy for another cancer within the last 3 years - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.